- AbbVie (NYSE:ABBV) has completed its acquisition of depression asset bretisilocin from Gilgamesh Pharmaceuticals.
- The candidate, currently in phase 2, is considered a psychedelic compound and a short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser under investigation for major depressive disorder.
- In August, AbbVie said it would acquire bretisilocin for up to $1.2B.
AbbVie finishes acquisition of depression asset bretisilocin from Gilgamesh
